Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon
Karo Healthcare (‘Karo’) has today completed the previously announced acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd. (‘Haleon’) for a total consideration of GBP 235m (EUR 274m). All the necessary conditions for the completion of this transaction have been fully met. Lamisil is a leading brand for the treatment of fungal infections like Athlete’s foot[1], and with a net sales of EUR 65m in 2022 the brand significantly strengthens our position in the Foot Health category. “We are proud to welcome Lamisil to our Karo family and look